Compare Amphastar Pharmaceuticals Inc (AMPH) vs HubSpot Inc (HUBS) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

HubSpot (HUBS) trades at $210.35, up 3.91% today, but remains in a bearish technical trend with strong selling pressure on moving averages. The company shows solid revenue growth with Q2 2026 earnings beating estimates at $3.26 EPS, though recent guidance cuts and a securities fraud investigation have created significant volatility. Fundamentals reveal strong gross margins of 83.25% but modest net income margins of 4.26%, with valuation metrics indicating premium pricing at P/E 74.89 and P/S 3.22.

The outlook is mixed with 76.59% analyst buy ratings and a $233.93 consensus target suggesting 11% upside, but near-term risks from customer growth slowdown and legal challenges weigh on sentiment. Long-term AI transformation strategy offers potential, but execution risks and competitive pressures require careful monitoring for investors considering entry at current levels.